GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Beginning Cash Position

Oncodesign Precision Medicine (XPAR:ALOPM) Beginning Cash Position : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Beginning Cash Position?

Oncodesign Precision Medicine's Beginning Cash Position for the quarter that ended in Dec. 2024 was €0.00 Mil.


Oncodesign Precision Medicine Beginning Cash Position Historical Data

The historical data trend for Oncodesign Precision Medicine's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Beginning Cash Position Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Beginning Cash Position
- - - - -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Beginning Cash Position Get a 7-Day Free Trial - - - - -

Oncodesign Precision Medicine Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Oncodesign Precision Medicine Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines